Why Intercept Pharmaceuticals Stock Got Crushed in March
Shares of the mid-cap biopharma Intercept Pharmaceuticals (NASDAQ: ICPT) fell by 31.5% during the month of March, according to data from S&P Global Market Intelligence. The drugmaker's shares hit the skids last month for two reasons:
Image source: Getty Images.
Intercept has a real shot at becoming the first company to bring a NASH drug to market. That said, there are dozens of other drugs racing to hit the market as well. So any delay -- like the one announced last month -- could cost the company a significant amount in future revenue. Ocaliva, after all, may have serious trouble fending off would-be competitors in a crowded marketplace.
Source Fool.com
